Research Papers:

Down-regulation of interleukin 7 receptor (IL-7R) contributes to central nervous system demyelination

Xudan Lei, Shijiao Cai, Yang Chen, Jianlin Cui, Yajie Wang, Zongjin Li and Yuhao Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:28395-28407. https://doi.org/10.18632/oncotarget.16081

Metrics: PDF 1567 views  |   HTML 2424 views  |   ?  


Xudan Lei1, Shijiao Cai1, Yang Chen1, Jianlin Cui1, Yajie Wang1, Zongjin Li1, Yuhao Li1

1Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Nankai University School of Medicine, Tianjin 300071, China

Correspondence to:

Yuhao Li, email: liyuhao@nankai.edu.cn

Keywords: interleukin 7 receptor (IL-7R), demyelination, myelin basic protein, myelination, zebrafish

Received: November 08, 2016     Accepted: February 27, 2017     Published: March 10, 2017


Interleukin 7 receptor (IL-7R) has been associated with the pathogenesis of multiple sclerosis (MS), though the mechanisms are not clear. Because myelin expression is highly conserved between zebrafish and mammals, zebrafish have become an ideal model for studying demyelination. We used a transgenic (Tg; mbp:nfsB-egfp) zebrafish line in which oligodendrocytes expressed green fluorescent protein (GFP) from the larval stage to adulthood. Exposing adult transgenic zebrafish to metronidazole induced demyelination that resembled the morphological changes associated with the early stages of MS. The metronidazole-induced demyelination was confirmed by magnetic resonance imaging (MRI) for the first time. Microarray analysis revealed down-regulation of IL-7R during demyelination. Targeted knockdown of IL-7R demonstrated that IL-7R is essential for myelination in embryonic and larval zebrafish. Moreover, IL-7R down-regulation induced signaling via the JAK/STAT pathway leading to apoptosis in oligodendrocytes. These findings contribute to our understanding of the role of IL-7R in demyelination, and provide a rationale for the development of IL-7R-based therapies for MS and other demyelinating diseases.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16081